Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Pretty Obvious Some avatars dont ;like this news
GSK 7.13% Yield for this financial year
Dividends count, if you want 2% and debt then buy AZN, but you wont get any dividend worth having, as the company borrows £ billions to pay its dividend and the CEO takes $21.7 million in pay and bonuses.
GSK out performs all FTSE companys and as the least debt , and as not plunged the country into debt with Furlough.
Suppose investors think IAQ, Rolls Royce , etc are well run companys, but when you see the 10's of £ billions of debt they have just added in the last year, it does make one wonder .
* AZN dividend is well covered from this year.
If AZN want some cash they can start selling down their Moderna stake,
now valued at over $5 billion.
Would hope we are somewhere near the GSK low here, barring something
unexpected.
* According to The Times AZN has very recently sold it's stake
in Moderna for more than $1 billion.
I literacy saw the news report having posted.
Read reports previously the stake was valued at over $5 billion.
If the Times report is accurate looks a huge overestimate, if $1 bn
relates to their entire holding.
Fats.
Going through SEC filings, in 2013 AZN paid $241 million for its 1.26% stake. it invested a further 320 million upto 2016 band increased its stake to 7.6%, but then sold down , and was further decreased when Moderna did its IPO in Dec 2018. AZN also had to it pay Royalty payments to Moderna totaling $310 million.
In 2017 Moderna had raised over $4.4 billion in series 2 equity stakes
Filings now show it sold its entire stake for just over $1 billion
Controversy rained down on Trump when he appointed Moncef Slaoui who owned shares in Moderna and GSK and that was and is a conflict of interest, the same as a UK https://www.standard.co.uk/news/uk/patrick-vallance-vaccine-shares-denies-conflict-interest-a4555141.html
Once trump appointed Moncef Slaoui as waarp speed chief and then gave Moderna $700 million in a first payment
Trump had attempted to buy Curevac with his hedge fund buddies and move to the USA
Merkel blocked it and GSK £104 million stake in Curevac for 10% stands at $1.8 billion.
Thanks for the clarification, I asked for my post mentioning $5 bn
to be removed, but that's not being done.
* been done.
SMT increased their investment in Moderna in January by 2.1 % giving them 3.1 % very good business. Be interesting to see full portfolio for February next.
Fats, this is all complete BS spouted by CS and cretins in my opinion.
If you think Morderna is a good buy, then I would question that as the SP as topped out several times at $160, the shares in issue is a real problem compared to CVAC, and the capital raise they did last year was at supid price.
They issued 27 million shares to raise $1.2 billion, but already had Warp pseed capital, Lonza on board making the vaccine.
Perfect example of Germa know how is, CVAC raised $490 million, by increasing shares in issue by 2.5 million at $95.00, and not diluting existing shareholders and they had no warp speed payment, Merkel to Trump and is clowns to do one.
GSK are just cannon fodder for London Cr00ks and others , its now a matter of garnering enough votes to dispatch EW
Do I think Moderna is a good buy?, have no interest in the company
other than the AZN stake, which is now outed.
I'm guessing AZN made net over $600 million plus,
so for Astra not be bad a return for a small 'sideline'.
It's pretty much immaterial though, given the AZN market cap.
Fatsprofit
AZN have made royalty payments to MRNA of over $300 million.
I did not get any comment from GSK on a Dividend cut this year, when I liaised with the non exec director, the communication back was no plans to cut the dividend.
AZN Alexion still have royalty payments to make to MRNA for Oncology and immunology, which are separate from Vaccine mRNA, according to the sec filings, but I will say, you need to study all the sec filings and prospectuses they issued in the last 28 months.
I will be interested to see what CS say about CVAC tomorrow , remembering Switzerland Vaccine orders apid for to CVAC, it should not make a difference, but I would imagine JW of CS will tread carefully this time